FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902287712> ?p ?o ?g. }

• W2902287712 abstract "Pomalidomide (POM) is a second-generation immunomodulatory agent with proven efficacy in patients with relapsed/refractory multiple myeloma (RRMM) proven to be refractory to previous treatment with lenalidomide (LEN) and bortezomib. We herein conducted a retrospective analysis of 14 RRMM patients receiving POM to determine its tolerability and safety in the clinical setting. The median age of the patients was 72 years (range, 58-84 years), and 85.7% of the patients were aged >70 years. The most frequent treatment dose was 3 mg/day. POM dose reductions were required in 54.5% (6/11) of the patients. The patient data were compared among three age groups (<70, 70-75 and >75 years) and there was only significant difference in daily POM treatment dose. The tolerability of POM must be confirmed, particularly in elderly patients. Dose reduction from 4 to 3 mg occurred during the second cycle in 83.3% (5/6) of the patients. It is important to determine the tolerability of POM in the early phases of treatment. The most frequently reported grade 3/4 hematological adverse events were neutropenia (64.3%), anemia (64.3%) and thrombocytopenia (57.1%). Although the median number of treatment cycles was 4 (range, 1-13), 21.4% (3/14) of the patients with a performance status (PS) of 3 were administered only 1 treatment cycle. The tolerability of POM was low among patients with poor PS and an aggressive treatment introduction should be avoided. However, 21.4% (3/14) of the patients were able to continue treatment for >1 year and some patients received long-term therapy. POM does not require dose modification for renal function, and multiple capsule doses are available, which is an advantage of POM compared with LEN. POM may be administered to late-stage RRMM patients in a real-world clinical setting, but elderly patients or those with poor PS must be treated with caution. In this manner, the treatment options for RRMM patients may be expanded by assessing the tolerability and safety of POM." @default.
• W2902287712 created "2018-12-11" @default.
• W2902287712 creator A5013340536 @default.
• W2902287712 creator A5022225625 @default.
• W2902287712 creator A5030011319 @default.
• W2902287712 creator A5072988508 @default.
• W2902287712 creator A5080338484 @default.
• W2902287712 creator A5086736337 @default.
• W2902287712 date "2018-11-27" @default.
• W2902287712 modified "2023-09-30" @default.
• W2902287712 title "Tolerability and safety of real‑world use of pomalidomide in patients with relapsed/refractory multiple myeloma" @default.
• W2902287712 cites W2000069677 @default.
• W2902287712 cites W2020298011 @default.
• W2902287712 cites W2066700805 @default.
• W2902287712 cites W2091773528 @default.
• W2902287712 cites W2136541422 @default.
• W2902287712 cites W2140579395 @default.
• W2902287712 cites W2160088903 @default.
• W2902287712 cites W2328108183 @default.
• W2902287712 cites W2338437414 @default.
• W2902287712 cites W2394652810 @default.
• W2902287712 cites W2487601053 @default.
• W2902287712 cites W2580225813 @default.
• W2902287712 cites W2582819487 @default.
• W2902287712 cites W2588506860 @default.
• W2902287712 cites W2598721019 @default.
• W2902287712 cites W2614781853 @default.
• W2902287712 cites W2750771620 @default.
• W2902287712 cites W2759041666 @default.
• W2902287712 cites W2770457793 @default.
• W2902287712 cites W2785647909 @default.
• W2902287712 cites W2790994467 @default.
• W2902287712 doi "https://doi.org/10.3892/mco.2018.1775" @default.
• W2902287712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6327207" @default.
• W2902287712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30680210" @default.
• W2902287712 hasPublicationYear "2018" @default.
• W2902287712 type Work @default.
• W2902287712 sameAs 2902287712 @default.
• W2902287712 citedByCount "5" @default.
• W2902287712 countsByYear W29022877122019 @default.
• W2902287712 countsByYear W29022877122021 @default.
• W2902287712 countsByYear W29022877122022 @default.
• W2902287712 crossrefType "journal-article" @default.
• W2902287712 hasAuthorship W2902287712A5013340536 @default.
• W2902287712 hasAuthorship W2902287712A5022225625 @default.
• W2902287712 hasAuthorship W2902287712A5030011319 @default.
• W2902287712 hasAuthorship W2902287712A5072988508 @default.
• W2902287712 hasAuthorship W2902287712A5080338484 @default.
• W2902287712 hasAuthorship W2902287712A5086736337 @default.
• W2902287712 hasBestOaLocation W29022877121 @default.
• W2902287712 hasConcept C121332964 @default.
• W2902287712 hasConcept C126322002 @default.
• W2902287712 hasConcept C142424586 @default.
• W2902287712 hasConcept C197934379 @default.
• W2902287712 hasConcept C2776063141 @default.
• W2902287712 hasConcept C2776364478 @default.
• W2902287712 hasConcept C2777063308 @default.
• W2902287712 hasConcept C2777478702 @default.
• W2902287712 hasConcept C2778375690 @default.
• W2902287712 hasConcept C2778524551 @default.
• W2902287712 hasConcept C2778850193 @default.
• W2902287712 hasConcept C29730261 @default.
• W2902287712 hasConcept C71924100 @default.
• W2902287712 hasConcept C87355193 @default.
• W2902287712 hasConceptScore W2902287712C121332964 @default.
• W2902287712 hasConceptScore W2902287712C126322002 @default.
• W2902287712 hasConceptScore W2902287712C142424586 @default.
• W2902287712 hasConceptScore W2902287712C197934379 @default.
• W2902287712 hasConceptScore W2902287712C2776063141 @default.
• W2902287712 hasConceptScore W2902287712C2776364478 @default.
• W2902287712 hasConceptScore W2902287712C2777063308 @default.
• W2902287712 hasConceptScore W2902287712C2777478702 @default.
• W2902287712 hasConceptScore W2902287712C2778375690 @default.
• W2902287712 hasConceptScore W2902287712C2778524551 @default.
• W2902287712 hasConceptScore W2902287712C2778850193 @default.
• W2902287712 hasConceptScore W2902287712C29730261 @default.
• W2902287712 hasConceptScore W2902287712C71924100 @default.
• W2902287712 hasConceptScore W2902287712C87355193 @default.
• W2902287712 hasLocation W29022877121 @default.
• W2902287712 hasLocation W29022877122 @default.
• W2902287712 hasLocation W29022877123 @default.
• W2902287712 hasLocation W29022877124 @default.
• W2902287712 hasOpenAccess W2902287712 @default.
• W2902287712 hasPrimaryLocation W29022877121 @default.
• W2902287712 hasRelatedWork W1998735674 @default.
• W2902287712 hasRelatedWork W2021159149 @default.
• W2902287712 hasRelatedWork W2039196526 @default.
• W2902287712 hasRelatedWork W2059075557 @default.
• W2902287712 hasRelatedWork W2128903704 @default.
• W2902287712 hasRelatedWork W2400769328 @default.
• W2902287712 hasRelatedWork W2792859185 @default.
• W2902287712 hasRelatedWork W2806380367 @default.
• W2902287712 hasRelatedWork W2902287712 @default.
• W2902287712 hasRelatedWork W3016752922 @default.
• W2902287712 isParatext "false" @default.
• W2902287712 isRetracted "false" @default.
• W2902287712 magId "2902287712" @default.
• W2902287712 workType "article" @default.